Pathophysiology of Chronic Rhinosinusitis without Nasal Polyp and Met-analysis of its Pharmaceutical Options

A Weta-analysis Study
Submitted for partial fulfillment of master degree
in Otorhinolaryngology

Presented by

Tarek Mohamed Gamal El-Din Hassan Ashmawy

M.B.B.Ch.

Under Supervision of

Prof. Dr. Ayman Mohamed Othman El-Kahky

Professor of Otorhinolaryngology Faculty of Medicine – Ain Shams University

Prof. Dr. Amr Gouda Shafik

Professor of Otorhinolaryngology Faculty of Medicine – Ain Shams University

Prof. Dr. Mohamed Shehata Taha

Professor of Otorhinolaryngology Ain Shams University Hospitals

Faculty of Medicine

Ain Shams University

2016



سورة البقرة الأية: ٣٢

Acknowledgments

First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.

I would like to express my sincerest gratitude and appreciation to **Prof. Dr. Ayman Mohamed Othman El Kahky,** for his constructive suggestions and motivations during the planning and development of this research work.

I would like to express the deepest appreciation to my **Prof. Dr. Amr Gouda Shafik,** for his patient guidance, insightful comments, unceasing encouragement and useful appraisals of this research work.

I would also like to thank **Prof. Dr. Mohamed Shehata Taha,** for his excellent guidance, valuable advice and assistance in keeping my progress on schedule.

Last but not least, I can't fort to thank all members of my family, especially my **Parents**, for their care and support.

Candidate

🖎 Tarek Mohamed Gamal

Contents

Subject	Page No.
List of Abbreviations	i
List of Tables	iii
List of Figures	v
Introduction	1
Aim of the Study	4
Review of Literature	
Anatomy of Paranasal Sinuses	5
Pathophysiology of chronic rhinosinusitis	
Predisposing Factors of Chronic Rhinosinusitis	
Surgery and Chronic Rhinosinusitis	22
Overview of the Different Pharmaceutical Opti	ons 25
Stress and Allergic Rhinitis	38
Patients and Methods	46
Results	49
Discussion	85
Conclusion	94
Recommendations	95
Summary	96
References	99
Summary in Arabic	

List of Abbreviations

List of Applications

Full-term

AAAAI : American academy of allergy, asthma and immunology

AAOA : American Academy of Otolaryngic Allergy

ACAAI : American College of Allergy, Asthma and Immunology

ACTH : Adrenocorticotrophic hormone

ANS : Autonomic nervous system

BSACI: British society for allergy and clinical immunology

CF : Cystic fibrosis

Abbr.

CGRP : Calcitonin gene-related peptide

CI : Confidence interval

CNS : Central nervous system

CRH : Corticotrophin releasing hormone

CRS : Chronic rhinosinusitis,

CRSsNP : Chronic rhinosinusitis without nasal polyp

CRSwNP: Chronic rhinosinusitis with nasal polyp

EPOS : European position paper on rhinosinusitis and nasal polyp

FDA : Food and drug administration

FEM : Fixed effect model

GABA : γ -amino butyric acid

HPA : Hyphophyseal-pituitary - adrenal

IL : Interleukin

JCAAI: Joint council of allergy, asthma and immunology

LTD4 : Leukotriene receptor antagonist 4

MMPI: Minnesota Multiphasic Personality Inventory profiles

NGF : Neuron growth factor

NO : Nitric oxide

OMC : Osteomeatal complex

pSmad : Phosphorylated smad cells

REM : Random effect model

SNOT : Sinonasal outcome treatment score

SP : Substance p

TGF-b: Tissue growth factor b

TH-1 : T -helper 1 cell

TH2 : T-helper 2 cell

TNFα : Tumor necrosis factor alpha

VAS : Visual analog scale

VIP : Vasoactive intestinal peptide

V1 : Ophthalmic branch of trigeminal

V2 : Maxillary branch of trigeminal

List of Tables

Cable No	. Title Page No
Table (1):	Expert Committee recommendations for oral corticosteroid therapy for chronic rhinosinusitis without nasal polyps
Table (2):	Allergic rhinitis treatment based on Symptoms
Table (3):	Treatment evidence and recommendations for adults with chronic rhinosinusitis without nasal polyps
Table (4):	Relationship between grade of recommendation, level of evidence and type of study
Table (5):	The results of search by different key words
Table (6):	Included articles
Table (7):	Excluded articles and reasons for exclusion
Table (8):	Studies involved in nasal irrigation55
Table (9):	Studies involved in topical antibacterial drugs
Table (10):	Studies involved in topical antifungal drugs
Table (11):	Studies involved in oral steroids 58
Table (12):	Studies involved in oral antifungal drugs 59
Table (13):	Studies involved in oral antihistamines 59

Table (14):	Studies involved in oral antibacterial drugs
Table (15):	Studies involved in topical steroids 60
Table (16):	Studies involved in combination therapy 61
Table (17):	Meta-analysis for improvement rate associated with monotherapy
Table (18):	Meta-analysis for improvement rate associated with nasal irrigation
Table (19):	Meta-analysis for improvement rate associated with oral antifungals71
Table (20):	Meta-analysis for improvement rate associated with oral antihistamines
Table (21):	Meta-analysis for improvement rate associated with oral corticosteroids
Table (22):	Meta-analysis for improvement rate associated with systemic antibiotics
Table (23):	Meta-analysis for improvement rate associated with topical antibacterials79
Table (24):	Meta-analysis for improvement rate associated with topical antifungals
Table (25):	Meta-analysis for improvement rate associated with topical corticosteroids83
Table (26):	Summary of each pharmaceutical option in relation to its statistical significance, improvement rate and -p- value

List of Figures

Figure No.	Citle Page C	No.
Figure (1):	Coronal CT scan shows maxillary ostium	6
Figure (2):	Concha Bullosa	7
Figure (3):	Uncinate process variations	9
Figure (4):	Haller cell	10
Figure (5):	Ethmoidal bulla, Uncinate and Middle turbinate	11
Figure (6):	Agger nasi cell	12
Figure (7):	Blood supply of PNS	13
Figure (8):	Venous drainage of Frontal sinus	14
Figure (9):	Nerve Supply of Lateral wall of nose	15
Figure (10):	TGF Expression in CRSsNP and CRSwNP	18
Figure (11):	Management of CRSsNP in adults scheme	34
Figure (12):	Stress and allergy disease paradigm	45
Figure (13):	Forest plot for improvement rate associated with all monotherapy	67
Figure (14):	Funnel plot for publication bias as regards improvement rate associated with all monotherapy	68
Figure (15): 1	Forest plot for improvement rate associated with nasal irrigation.	70
Figure (16):	Funnel plot for improvement rate associated with nasal irrigation.	70
Figure (17):	Forest plot for improvement rate associated with oral antifungals.	

Figure (18):	Funnel plot for improvement rate associated with oral antifungals.	72
Figure (19):	Forest plot for improvement rate associated with oral antihistamines.	74
Figure (20):	Funnel plot for improvement rate associated with oral antihistamines.	74
Figure (21):	Forest plot for improvement rate associated with oral corticosteroids.	76
Figure (22):	Funnel plot for improvement rate associated with oral corticosteroids.	76
Figure (23):	Forest plot for improvement rate associated with systemic antibiotics.	78
Figure (24):	Funnel plot for improvement rate associated with systemic antibiotics.	78
Figure (25):	Forest plot for improvement rate associated with topical antibacterials.	80
Figure (26):	Funnel plot for improvement rate associated with topical antibacterials.	80
Figure (27):	Forest plot for improvement rate associated with topical antifungals	82
Figure (28):	Funnel plot for improvement rate associated with topical antifungals.	82
Figure (29):	Forest plot for improvement rate associated with topical corticosteroids.	84
Figure (30):	Funnel plot for improvement rate associated with topical corticosteroids.	

Introduction

Chronic sinusitis is defined as sinusitis with symptoms of nasal obstruction, discharge, facial pain and pressure together with hyposmia supported by subjective endoscopic and CT findings persisting for at least 8 to 12 weeks, despite appropriate medical therapy. Alternatively, rhinosinusitis may be considered chronic in a patient experiencing four or more episodes annually of recurrent acute sinusitis, each lasting at least 10 days, in association with persistent changes on CT scan for 4-6 weeks following medical treatment. The cause of chronic sinusitis is poorly understood, the most widely held view being that it is established as a result of interference with normal sinus clearance mechanisms, leading to colonization with bacteria normally resident in the nose and nasopharynx and their subsequent proliferation (Meltzer et al., 2004).

Allergic rhinitis is a variant of chronic rhinosinusitis without nasal polyp and is mediated with immunoglobulin E, thought to occur after exposure to indoor and outdoor allergens such as dust mites, insects, molds, animal danders and pollens. Symptoms include rhinorrhea, nasal congestion, obstruction, and itching. Optimal treatment includes avoidance of the allergen, targeted symptom control and immunotherapy (Nelson, 2000).

Chronic rhinosinusitis has two types, chronic rhinosinusitis with nasal polyp and without nasal polyp. This study is focused on chronic rhinosinusitis without nasal polyp so as to narrow and focus the study, also incidence of chronic rhinosinusitis without nasal polyp versus chronic rhinosinusitis with nasal polyp is 1048 versus 83 per 100000 patient between 2007 and 2009 respectively in Geisinger Clinic in central Pennsylvania in United States (Tan et al., 2013).

In 2012 national health survey Lethbridge-Cejku reported 12% of the US population (nearly 1 in 8 adults) being diagnosed with chronic rhinosinusitis (Lethbridge-Cejku M; et al., 2006).

National ambulatory care data from 2006 to 2010 conducted annually by the United States Department of Health and Human Services revealed that rhinosinusitis accounted for more prescriptions of antibiotic than any other diagnosis and accounted for 11% of all antibiotic visits of the primary care patients with chronic rhinisinusitis (Smith et al., 2013).

CRS can also have a significant impact on healthrelated quality of life. Patients with CRS referred to otolaryngologists score significantly lower values on measures of bodily pain and social functioning than do those with angina, back pain, congestive heart failure, and chronic obstructive pulmonary disease. Similarly, patients with CRS have health utility scores that are worse than many chronic diseases, including heart failure, coronary artery disease, and chronic obstructive pulmonary disease. Moreover, treatment of chronic rhinosinusitis can improve health state score values and significantly reduce fatigue and bodily pain (Bhattacharyya, 2011).

Aim of the Study

meta-analysis study to provide an evidence based approach for the use of different pharmaceutical agents in the management of chronic rhinosinusitis without nasal polyp with an overview of the pathophysiology of chronic rinosinusitis without nasal polyp.

Chapter 1 Anatomy of Paranasal Sinuses

Inderstanding the normal anatomy and physiology of the sinuses is important to understand the pathogenesis of sinus disease. There are four pairs of sinuses named for the bones of the skull they pneumatize. They are the maxillary, ethmoid, frontal and sphenoid sinus air cells and they are lined by pseudostratified columnar epithelium bearing cilia. The mucosa contains goblet cells that secrete mucus, which aids in trapping inhaled particles and debris. The uncinate process is a sickle-shaped bone extension of the medial maxillary wall that extends anterosuperiorly to posteroinferiorly. The uncinate process is rarely pneumatized. The hiatus semilunaris, situated immediately superior to the uncinate process, is a slit like air-filled space anterior and inferior to the largest ethmoid air cell, the ethmoidal bulla. It is clinically significant because disease located here results in obstruction of the ipsilateral maxillary antrum, anterior and middle ethmoid air cells and frontal sinus, whereas disease in the infundibulum results in isolated obstruction of the ipsilateral maxillary sinus alone (Arash et al., 2007).

The ethmoid sinuses are paired, discrete cells that may number 18 or more. They are anatomically divided into anterior and posterior groups according to the location of the draining